CytomX, which is developing cancer immunotherapies that do not target healthy cells, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The San Francisco, CA-based company, which was founded in 2008 and booked $8 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol CTMX. BofA Merrill Lynch, Jefferies and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
